| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 18 | 2025 | 556 | 2.970 |
Why?
|
| Osteomyelitis | 12 | 2024 | 207 | 2.400 |
Why?
|
| Haemophilus Infections | 4 | 2025 | 97 | 2.230 |
Why?
|
| Haemophilus influenzae | 4 | 2025 | 135 | 2.230 |
Why?
|
| Myocarditis | 7 | 2013 | 124 | 1.770 |
Why?
|
| Streptococcal Infections | 8 | 2024 | 246 | 1.760 |
Why?
|
| Bacteremia | 9 | 2025 | 420 | 1.700 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 10 | 2025 | 231 | 1.550 |
Why?
|
| Meningitis, Bacterial | 5 | 2022 | 96 | 1.510 |
Why?
|
| Anti-Bacterial Agents | 24 | 2024 | 2503 | 1.450 |
Why?
|
| Staphylococcus aureus | 13 | 2024 | 467 | 1.360 |
Why?
|
| Arthritis, Infectious | 7 | 2025 | 65 | 1.300 |
Why?
|
| Vancomycin | 6 | 2023 | 221 | 1.260 |
Why?
|
| Cardiovirus Infections | 4 | 2012 | 6 | 1.090 |
Why?
|
| Streptococcus agalactiae | 7 | 2022 | 102 | 1.080 |
Why?
|
| Toll-Like Receptor 3 | 4 | 2013 | 19 | 1.040 |
Why?
|
| Bacteria | 2 | 2021 | 502 | 1.010 |
Why?
|
| Sinusitis | 3 | 2024 | 116 | 0.930 |
Why?
|
| Streptococcus anginosus | 2 | 2024 | 9 | 0.860 |
Why?
|
| Hospitalization | 3 | 2025 | 1875 | 0.840 |
Why?
|
| Otitis Media | 2 | 2024 | 89 | 0.810 |
Why?
|
| Disease Management | 3 | 2021 | 541 | 0.780 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2021 | 3 | 0.730 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2021 | 5 | 0.730 |
Why?
|
| Hospitals, Pediatric | 3 | 2025 | 776 | 0.710 |
Why?
|
| Myocardium | 8 | 2012 | 847 | 0.700 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2012 | 358 | 0.700 |
Why?
|
| Child, Preschool | 27 | 2025 | 14343 | 0.690 |
Why?
|
| Texas | 10 | 2025 | 3549 | 0.660 |
Why?
|
| Staphylococcus | 2 | 2018 | 67 | 0.660 |
Why?
|
| Hemoglobinopathies | 1 | 2019 | 17 | 0.630 |
Why?
|
| Microbial Sensitivity Tests | 11 | 2023 | 811 | 0.620 |
Why?
|
| Child | 34 | 2025 | 25094 | 0.610 |
Why?
|
| Infant | 25 | 2025 | 12765 | 0.580 |
Why?
|
| Cerebral Ventriculitis | 1 | 2017 | 16 | 0.540 |
Why?
|
| Escherichia coli Infections | 1 | 2019 | 184 | 0.540 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2018 | 97 | 0.540 |
Why?
|
| Membrane Glycoproteins | 8 | 2011 | 416 | 0.510 |
Why?
|
| Toll-Like Receptors | 6 | 2011 | 81 | 0.510 |
Why?
|
| Receptors, Cell Surface | 6 | 2004 | 424 | 0.510 |
Why?
|
| Incidence | 8 | 2025 | 3249 | 0.480 |
Why?
|
| Anemia, Sickle Cell | 1 | 2019 | 325 | 0.470 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2009 | 638 | 0.470 |
Why?
|
| Signal Transduction | 11 | 2013 | 4482 | 0.470 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2010 | 207 | 0.460 |
Why?
|
| Infant, Newborn | 14 | 2025 | 8358 | 0.460 |
Why?
|
| Adolescent | 17 | 2025 | 19994 | 0.450 |
Why?
|
| Immunity, Innate | 6 | 2012 | 395 | 0.430 |
Why?
|
| Humans | 63 | 2025 | 126848 | 0.420 |
Why?
|
| Retrospective Studies | 21 | 2025 | 16986 | 0.420 |
Why?
|
| Maus Elberfeld virus | 1 | 2012 | 1 | 0.400 |
Why?
|
| Male | 36 | 2025 | 62565 | 0.400 |
Why?
|
| Toll-Like Receptor 2 | 6 | 2012 | 55 | 0.390 |
Why?
|
| Autophagy | 2 | 2013 | 404 | 0.390 |
Why?
|
| Female | 33 | 2025 | 68387 | 0.390 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 234 | 0.380 |
Why?
|
| Cytokines | 8 | 2012 | 1318 | 0.380 |
Why?
|
| Candidiasis | 1 | 2013 | 108 | 0.370 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 110 | 0.370 |
Why?
|
| Encephalomyocarditis virus | 3 | 2011 | 6 | 0.370 |
Why?
|
| Enterovirus | 2 | 2010 | 52 | 0.360 |
Why?
|
| Monocytes | 3 | 2000 | 331 | 0.360 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 160 | 0.360 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2011 | 48 | 0.360 |
Why?
|
| Bacterial Typing Techniques | 2 | 2021 | 99 | 0.330 |
Why?
|
| Cardiomyopathies | 2 | 2013 | 494 | 0.320 |
Why?
|
| Toll-Like Receptor 4 | 7 | 2012 | 138 | 0.310 |
Why?
|
| Lipopolysaccharides | 6 | 2011 | 292 | 0.290 |
Why?
|
| Heart | 6 | 2011 | 651 | 0.290 |
Why?
|
| Fever of Unknown Origin | 2 | 2018 | 45 | 0.290 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 259 | 0.280 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 1996 | 229 | 0.280 |
Why?
|
| NF-kappa B | 4 | 2003 | 440 | 0.260 |
Why?
|
| Multilocus Sequence Typing | 3 | 2023 | 62 | 0.250 |
Why?
|
| Heat-Shock Response | 1 | 2006 | 33 | 0.250 |
Why?
|
| Receptors, Interleukin-1 | 3 | 2011 | 25 | 0.240 |
Why?
|
| Shock, Hemorrhagic | 1 | 2005 | 51 | 0.220 |
Why?
|
| Inflammation Mediators | 2 | 2005 | 222 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2022 | 3690 | 0.220 |
Why?
|
| Heart-Assist Devices | 1 | 2013 | 1045 | 0.210 |
Why?
|
| Mice | 17 | 2012 | 17629 | 0.210 |
Why?
|
| Interleukin-1 | 5 | 2005 | 131 | 0.210 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2011 | 124 | 0.210 |
Why?
|
| Mastoiditis | 1 | 2024 | 33 | 0.210 |
Why?
|
| Acute Disease | 5 | 2025 | 1136 | 0.210 |
Why?
|
| Echocardiography | 2 | 2024 | 1113 | 0.210 |
Why?
|
| Brain Abscess | 1 | 2024 | 52 | 0.200 |
Why?
|
| Shock, Septic | 2 | 2002 | 147 | 0.200 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 561 | 0.200 |
Why?
|
| Animals | 22 | 2021 | 33194 | 0.200 |
Why?
|
| Mice, Knockout | 7 | 2012 | 3716 | 0.200 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 53 | 0.190 |
Why?
|
| Receptors, Virus | 1 | 2003 | 89 | 0.190 |
Why?
|
| Graft Rejection | 3 | 2018 | 553 | 0.190 |
Why?
|
| Cross Infection | 2 | 2016 | 333 | 0.190 |
Why?
|
| Leukocyte Count | 2 | 2019 | 247 | 0.180 |
Why?
|
| Rat-Bite Fever | 1 | 2021 | 4 | 0.180 |
Why?
|
| Streptobacillus | 1 | 2021 | 4 | 0.180 |
Why?
|
| Soft Tissue Infections | 1 | 2023 | 88 | 0.180 |
Why?
|
| Drug Monitoring | 1 | 2024 | 274 | 0.180 |
Why?
|
| Myocardial Contraction | 3 | 2008 | 239 | 0.180 |
Why?
|
| Drosophila Proteins | 3 | 2002 | 757 | 0.180 |
Why?
|
| Encephalitis | 1 | 2022 | 117 | 0.170 |
Why?
|
| Interleukin-6 | 3 | 2008 | 406 | 0.170 |
Why?
|
| Immunosuppressive Agents | 3 | 2018 | 651 | 0.170 |
Why?
|
| Endotoxins | 1 | 2001 | 46 | 0.170 |
Why?
|
| Cefazolin | 1 | 2020 | 19 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 2036 | 0.170 |
Why?
|
| Blood Culture | 1 | 2020 | 36 | 0.170 |
Why?
|
| Paranasal Sinuses | 1 | 2020 | 18 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 261 | 0.160 |
Why?
|
| Pott Puffy Tumor | 1 | 2020 | 4 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 248 | 0.160 |
Why?
|
| Ear, Inner | 1 | 2020 | 41 | 0.160 |
Why?
|
| Transcription Factor AP-1 | 1 | 2000 | 108 | 0.160 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 43 | 0.160 |
Why?
|
| Central Nervous System Infections | 1 | 2020 | 20 | 0.160 |
Why?
|
| Salmonella | 1 | 2019 | 30 | 0.160 |
Why?
|
| Bacterial Capsules | 2 | 1996 | 42 | 0.160 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 484 | 0.160 |
Why?
|
| Brain Infarction | 1 | 2019 | 28 | 0.150 |
Why?
|
| Mice, Transgenic | 4 | 2012 | 2314 | 0.150 |
Why?
|
| Medical Records | 1 | 2019 | 179 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 413 | 0.150 |
Why?
|
| Virus Replication | 2 | 2012 | 593 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 155 | 0.140 |
Why?
|
| Coagulase | 1 | 2018 | 22 | 0.140 |
Why?
|
| Bone Diseases, Infectious | 1 | 2018 | 9 | 0.140 |
Why?
|
| Models, Biological | 1 | 2003 | 1371 | 0.140 |
Why?
|
| Immunologic Factors | 2 | 2012 | 182 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2003 | 741 | 0.140 |
Why?
|
| Vibrio Infections | 1 | 1997 | 15 | 0.140 |
Why?
|
| Myocytes, Cardiac | 3 | 2008 | 609 | 0.130 |
Why?
|
| Fever | 2 | 2021 | 309 | 0.130 |
Why?
|
| Fanconi Anemia | 1 | 1997 | 40 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2021 | 12537 | 0.130 |
Why?
|
| Methicillin Resistance | 1 | 2017 | 116 | 0.130 |
Why?
|
| Apoptosis | 3 | 2012 | 1813 | 0.130 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 154 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2021 | 1195 | 0.130 |
Why?
|
| Viral Load | 3 | 2018 | 398 | 0.130 |
Why?
|
| Streptococcus | 1 | 1996 | 61 | 0.130 |
Why?
|
| Disease Models, Animal | 4 | 2012 | 4433 | 0.130 |
Why?
|
| Mutation | 1 | 2010 | 5947 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2019 | 282 | 0.120 |
Why?
|
| Pandemics | 1 | 2024 | 1136 | 0.120 |
Why?
|
| Brucella melitensis | 1 | 1996 | 8 | 0.120 |
Why?
|
| Liver Abscess | 1 | 1996 | 13 | 0.120 |
Why?
|
| Brucellosis | 1 | 1996 | 19 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 2 | 2018 | 217 | 0.120 |
Why?
|
| Central Nervous System | 1 | 2018 | 272 | 0.120 |
Why?
|
| Antigens, Bacterial | 2 | 1996 | 311 | 0.120 |
Why?
|
| Splenic Diseases | 1 | 1996 | 30 | 0.120 |
Why?
|
| Abdominal Abscess | 1 | 1996 | 24 | 0.120 |
Why?
|
| Penicillanic Acid | 1 | 2015 | 10 | 0.120 |
Why?
|
| Chlorhexidine | 1 | 2015 | 41 | 0.120 |
Why?
|
| Bacteriological Techniques | 1 | 2016 | 84 | 0.120 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 1995 | 3 | 0.120 |
Why?
|
| Radiography, Interventional | 1 | 2016 | 84 | 0.120 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2015 | 63 | 0.120 |
Why?
|
| Sepsis | 2 | 1997 | 493 | 0.110 |
Why?
|
| Cyclic GMP | 3 | 2004 | 90 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 377 | 0.110 |
Why?
|
| Antigen-Antibody Complex | 1 | 1994 | 59 | 0.110 |
Why?
|
| Caspase 3 | 2 | 2012 | 126 | 0.110 |
Why?
|
| Cell Membrane | 1 | 1996 | 449 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 925 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 2315 | 0.100 |
Why?
|
| Ganciclovir | 1 | 1994 | 100 | 0.100 |
Why?
|
| Sequestosome-1 Protein | 1 | 2013 | 15 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2002 | 90 | 0.100 |
Why?
|
| Age Factors | 1 | 2020 | 2790 | 0.100 |
Why?
|
| Pseudomonas | 1 | 2013 | 10 | 0.100 |
Why?
|
| Nitric Oxide Synthase | 3 | 2002 | 170 | 0.100 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2012 | 13 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2019 | 780 | 0.100 |
Why?
|
| United States | 3 | 2025 | 11310 | 0.100 |
Why?
|
| Candida | 1 | 2013 | 80 | 0.090 |
Why?
|
| Dexamethasone | 1 | 1994 | 261 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 6 | 2011 | 4513 | 0.090 |
Why?
|
| Antibodies, Bacterial | 1 | 1994 | 402 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 247 | 0.090 |
Why?
|
| Abscess | 2 | 2024 | 138 | 0.090 |
Why?
|
| Biopsy | 4 | 2018 | 1236 | 0.090 |
Why?
|
| HeLa Cells | 1 | 2013 | 685 | 0.090 |
Why?
|
| Heart Failure | 3 | 2012 | 2287 | 0.090 |
Why?
|
| Methicillin | 2 | 2023 | 43 | 0.090 |
Why?
|
| Phenotype | 2 | 2012 | 4311 | 0.090 |
Why?
|
| Protein Transport | 2 | 2010 | 350 | 0.090 |
Why?
|
| Infant, Premature, Diseases | 1 | 1994 | 236 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 1225 | 0.090 |
Why?
|
| Reperfusion Injury | 1 | 2012 | 108 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2013 | 760 | 0.090 |
Why?
|
| Chloramphenicol | 1 | 1991 | 25 | 0.090 |
Why?
|
| Meningitis, Haemophilus | 1 | 1991 | 34 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 784 | 0.090 |
Why?
|
| Cefotaxime | 1 | 1991 | 38 | 0.090 |
Why?
|
| Streptococcus pneumoniae | 2 | 2025 | 377 | 0.090 |
Why?
|
| Inactivation, Metabolic | 1 | 2011 | 28 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2013 | 769 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2011 | 1014 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 351 | 0.090 |
Why?
|
| Coxsackievirus Infections | 1 | 2010 | 10 | 0.080 |
Why?
|
| Chloroquine | 1 | 2010 | 30 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2012 | 508 | 0.080 |
Why?
|
| Endosomes | 1 | 2010 | 62 | 0.080 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2010 | 13 | 0.080 |
Why?
|
| Nitric Oxide | 2 | 2004 | 463 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 576 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2013 | 1538 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 523 | 0.080 |
Why?
|
| Interferons | 1 | 2010 | 133 | 0.080 |
Why?
|
| Ventricular Function, Left | 1 | 2012 | 515 | 0.070 |
Why?
|
| Time Factors | 3 | 2012 | 6137 | 0.070 |
Why?
|
| Prognosis | 3 | 2013 | 4770 | 0.070 |
Why?
|
| Mycophenolic Acid | 2 | 2018 | 57 | 0.070 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2011 | 321 | 0.070 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 14 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 782 | 0.070 |
Why?
|
| Community-Acquired Infections | 2 | 2021 | 249 | 0.070 |
Why?
|
| HMGB1 Protein | 1 | 2008 | 25 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1597 | 0.070 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2019 | 92 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2011 | 2905 | 0.070 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1992 | 475 | 0.070 |
Why?
|
| Hepatitis | 1 | 2008 | 55 | 0.070 |
Why?
|
| Parvovirus B19, Human | 2 | 2008 | 26 | 0.070 |
Why?
|
| Cell Line | 2 | 2010 | 2565 | 0.070 |
Why?
|
| Fetal Blood | 2 | 2000 | 171 | 0.070 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 46 | 0.070 |
Why?
|
| Glucuronosyltransferase | 1 | 2007 | 63 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2018 | 308 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2022 | 962 | 0.060 |
Why?
|
| Genotype | 1 | 2012 | 2600 | 0.060 |
Why?
|
| Risk Factors | 3 | 2020 | 10551 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 235 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2022 | 2061 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5113 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2546 | 0.060 |
Why?
|
| RNA Interference | 1 | 2008 | 495 | 0.060 |
Why?
|
| Base Sequence | 1 | 2010 | 2771 | 0.060 |
Why?
|
| Kingella kingae | 1 | 2025 | 7 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3601 | 0.060 |
Why?
|
| Myocardial Ischemia | 2 | 2005 | 299 | 0.060 |
Why?
|
| Caspase 1 | 1 | 2005 | 45 | 0.060 |
Why?
|
| Etanercept | 1 | 2005 | 44 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 73 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2012 | 931 | 0.060 |
Why?
|
| Mice, Inbred C3H | 2 | 2002 | 109 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2547 | 0.060 |
Why?
|
| Teichoic Acids | 2 | 2011 | 9 | 0.050 |
Why?
|
| Liver | 2 | 2011 | 1763 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2025 | 167 | 0.050 |
Why?
|
| Antitubercular Agents | 2 | 1996 | 263 | 0.050 |
Why?
|
| Pelvis | 1 | 2024 | 69 | 0.050 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2003 | 11 | 0.050 |
Why?
|
| Streptococcus pyogenes | 1 | 2024 | 80 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2005 | 581 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 132 | 0.050 |
Why?
|
| Dystrophin | 1 | 2003 | 41 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2000 | 119 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2016 | 380 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 196 | 0.050 |
Why?
|
| Outpatients | 1 | 2024 | 254 | 0.050 |
Why?
|
| Clindamycin | 1 | 2022 | 39 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2000 | 186 | 0.050 |
Why?
|
| Resuscitation | 1 | 2005 | 268 | 0.050 |
Why?
|
| Cytoskeleton | 1 | 2003 | 167 | 0.050 |
Why?
|
| Penicillins | 1 | 2023 | 153 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 763 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2025 | 308 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2022 | 136 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2004 | 257 | 0.040 |
Why?
|
| Hemodynamics | 2 | 2002 | 823 | 0.040 |
Why?
|
| Renal Dialysis | 2 | 2018 | 933 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 380 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2008 | 866 | 0.040 |
Why?
|
| Heart Ventricles | 2 | 2002 | 762 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 165 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2002 | 200 | 0.040 |
Why?
|
| Exanthema | 1 | 2021 | 73 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2003 | 573 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2000 | 64 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 732 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2007 | 1570 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2000 | 103 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 2000 | 101 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 670 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2000 | 203 | 0.040 |
Why?
|
| Adult | 4 | 2015 | 30413 | 0.040 |
Why?
|
| Protein Kinase C-epsilon | 2 | 2010 | 12 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 2018 | 34 | 0.040 |
Why?
|
| Enterobacter cloacae | 1 | 2018 | 13 | 0.040 |
Why?
|
| Histoplasma | 1 | 2018 | 37 | 0.040 |
Why?
|
| Imidazoles | 1 | 2000 | 217 | 0.040 |
Why?
|
| Pyridines | 1 | 2000 | 251 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2018 | 87 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2000 | 303 | 0.040 |
Why?
|
| Histoplasmosis | 1 | 2018 | 55 | 0.040 |
Why?
|
| Mice, Mutant Strains | 2 | 2010 | 365 | 0.030 |
Why?
|
| Sarcomeres | 2 | 2008 | 32 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2002 | 937 | 0.030 |
Why?
|
| Neutrophils | 1 | 2000 | 351 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 257 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 565 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2024 | 6201 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 978 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 1996 | 20 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1374 | 0.030 |
Why?
|
| Mupirocin | 1 | 2015 | 20 | 0.030 |
Why?
|
| Piperacillin | 1 | 2015 | 14 | 0.030 |
Why?
|
| Sex Distribution | 1 | 1996 | 314 | 0.030 |
Why?
|
| Rats | 1 | 2021 | 3388 | 0.030 |
Why?
|
| Gene Expression | 2 | 2011 | 1488 | 0.030 |
Why?
|
| Age Distribution | 1 | 1996 | 422 | 0.030 |
Why?
|
| Inflammation | 1 | 2002 | 1423 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 330 | 0.030 |
Why?
|
| Pyrazinamide | 1 | 1994 | 10 | 0.030 |
Why?
|
| Middle Aged | 2 | 2015 | 27695 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 1995 | 120 | 0.030 |
Why?
|
| Leg | 1 | 1995 | 125 | 0.030 |
Why?
|
| Genomics | 1 | 2022 | 1573 | 0.030 |
Why?
|
| Infection Control | 1 | 2015 | 157 | 0.030 |
Why?
|
| Isoniazid | 1 | 1994 | 64 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 209 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1193 | 0.030 |
Why?
|
| Rifampin | 1 | 1994 | 117 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2018 | 757 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1848 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2041 | 0.020 |
Why?
|
| Aged | 1 | 2010 | 20331 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2012 | 95 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 1220 | 0.020 |
Why?
|
| Survival Rate | 1 | 1996 | 2099 | 0.020 |
Why?
|
| Cefuroxime | 1 | 1991 | 14 | 0.020 |
Why?
|
| Subdural Effusion | 1 | 1991 | 8 | 0.020 |
Why?
|
| Ampicillin Resistance | 1 | 1991 | 18 | 0.020 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2011 | 9 | 0.020 |
Why?
|
| Epiglottitis | 1 | 1991 | 12 | 0.020 |
Why?
|
| Metabolic Detoxication, Phase II | 1 | 2011 | 14 | 0.020 |
Why?
|
| Hearing Loss, Bilateral | 1 | 1991 | 16 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1994 | 1138 | 0.020 |
Why?
|
| Cellulitis | 1 | 1991 | 59 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 1994 | 489 | 0.020 |
Why?
|
| Mutation, Missense | 2 | 2007 | 891 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2011 | 113 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1994 | 408 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2010 | 33 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2010 | 58 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 60 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1995 | 1861 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2011 | 231 | 0.020 |
Why?
|
| Prednisolone | 1 | 2009 | 56 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 648 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1994 | 823 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2009 | 119 | 0.020 |
Why?
|
| Chemokine CXCL2 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Cholic Acid | 1 | 2008 | 19 | 0.020 |
Why?
|
| Xanthenes | 1 | 2008 | 5 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 2008 | 34 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2008 | 48 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2008 | 18 | 0.020 |
Why?
|
| Parvoviridae Infections | 1 | 2008 | 34 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2008 | 52 | 0.020 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2008 | 28 | 0.020 |
Why?
|
| Calcium Channels, L-Type | 1 | 2008 | 49 | 0.020 |
Why?
|
| Cats | 1 | 2008 | 114 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 111 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2008 | 76 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 150 | 0.020 |
Why?
|
| Pneumonia | 1 | 1991 | 334 | 0.020 |
Why?
|
| Cell Separation | 1 | 2008 | 219 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 273 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2008 | 118 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 245 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 449 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2008 | 271 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 288 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2008 | 204 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 658 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2008 | 521 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2005 | 23 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 2005 | 86 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 156 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 33 | 0.010 |
Why?
|
| Cytoprotection | 1 | 2003 | 37 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 38 | 0.010 |
Why?
|
| Ligation | 1 | 2003 | 136 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2004 | 259 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 2110 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2002 | 165 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 9660 | 0.010 |
Why?
|
| Opsonin Proteins | 1 | 2000 | 19 | 0.010 |
Why?
|
| Respiratory Burst | 1 | 2000 | 9 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2000 | 85 | 0.010 |
Why?
|
| Pregnancy | 1 | 1992 | 7412 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2003 | 524 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 827 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2000 | 191 | 0.010 |
Why?
|
| Ligands | 1 | 2000 | 477 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2000 | 338 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 2002 | 629 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 758 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1597 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 2972 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 3584 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 988 | 0.010 |
Why?
|